Postmortem serotonin (5-HT) concentrations in the cerebrospinal fluid of medicolegal cases

Forensic Science International

Volumn 142, Issue 2-3, 2004, Pages 211-219

  Musshoff, F ^a   Menting, T ^a   Madea, B ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cerebrospinal fluid (CSF); Opiates; Serotonin (5 HT); Suicides

Indexed keywords

OPIATE; SEROTONIN;

ADULT; AGED; ALCOHOL BLOOD LEVEL; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MEDICOLEGAL ASPECT; OCCIPITAL CORTEX; PRIORITY JOURNAL; SUICIDE;

EID: 2542457350     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2004.02.023     Document Type: Article

References (93)

1. Asberg M. Neurotransmitters and suicidal behaviour. The evidence from cerebrospinal fluid studies. Ann. N. Y. Acad. Sci. 836:1997;158-181
2. Brunner J., Bronisch T. Neurobiologische Korrelate suizidalen Verhaltens. Fortschr. Neurol. Psychiatr. 67:1999;391-412
3. Mann J.J. Neurobiology of suicidal behaviour. Neuroscience. 4:2003;819-828
4. Korpi E.A., Kleinman J.E., Goodman S.I., Phillips I., DeLisi L.E., Linnoila M., Wyatt R.J. Serotonin and 5-hydroxyindolacetic acid in brains of suicide victims. Arch. Gen. Psychiatry. 43:1986;594-600
5. Mann J.J., Malone K.M. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol. Psychiatry. 41:1997;162-171
6. Cremniter D., Jamain S., Kollenbach K., Alvarez J.C., Lecrubier Y., Gilton A., Jullien P., Lesieur P., Bonnet F., Spreux-Varoquaux O. CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects. Biol. Psychiatry. 45:1999;1572-1579
7. Placidi G.P., Oquendo M.A., Malone K.M., Huang Y.Y., Ellis S.P., Mann J.J. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol. Psychiatry. 50:2001;783-791
8. Stanley M., Virgilio J., Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 216:1982;1337-1339
9. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the venterolateral prefrontal cortex of suicide victims. Brain Res. 688:1995;121-133
10. Mann J.J., Henteleff R.A., Lagattuta T.F., Perper J.A., Li S., Arango V. Lower 3H-paroxetin binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites. J. Neural Transm. 103:1996;1337-1350
11. Rosel P., Arranz B., Vallejo J., Oros M., Menchon J.M., Alvarez P., Navarro M.A. High affinity [3H]imipramine and [3H]paroxetin binding sites in suicide brains. J. Neural Transm. 104:1997;921-929
12. Mann J.J. The neurobiology of suicide. Nat. Med. 4:1998;25-30
13. Stanley B., Mann J.J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 29:1983;214-216
14. Arora R.C., Meltzer H.Y. Serotonergic measures in the brain of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am. J. Psychiatry. 146:1989;730-736
15. Arango V., Ernsberger P., Marzuk P.M., Chen J.S., Tierney H., Stanley M., Reis D.J., Mann J.J. Autoradiographic demonstration of increased serotonin 5-HT2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch. Gen. Psychiatry. 47:1990;1038-1047
16. Mann J.J., Stanley B., McBride P.A., McExen S. Increased serotonin2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry. 43:1986;954-959
17. Hrdina P.D., Demeter E., Vu T.B., Sotonyi P., Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res. 614:1993;37-44
18. Arango V., Underwood M.D., Mann J.J. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann. N. Y. Acad. Sci. 836:1997;269-287
19. Mann J.J., Brent D., Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology. 24:2001;467-477
20. Brunner J., Bronisch T. Genetics and neurobiology of suicidal behaviour - implications for psychopharmacotherapy and psychotherapy. Psychotherapy. 7:2002;260-272
21. Shaw D.M., Camps F.E., Eccleston E.G. 5-Hydroxytryptamine in the hindbrain of depressive suicides. Br. J. Psychiatr. 113:1967;1407-1411
22. Lloyd K.G., Fareley I.J., Deck J.H.N., Hornykiewicz O. Serotonin and 5-hydroxyindolacetic acid in discrete areas of brainstem of suicide victims and control patients. Adv. Biochem. Psychopharmacol. 11:1974;387-397
23. Pare C.M.B., Yeung D.P.H., Price K., Stacey R.S. 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas-poisoning. Lancet. II:1969;133-135
24. Stanley M., Stanley B. Postmortem evidence for serotonin's role in suicide. J. Clin. Psychiatry. 51:1990;22-28
25. Arato M., Falus A., Tothfalusi L., Magyar K., Sotonyi P., Somogyi E. Postmortem cerebrospinal fluid measurements in suicides. Acta Med. Log. Soc. 36:1986;120-125
26. G. Kauert, T. Zucker, T. Gilg, W. Eisenmenger, Measurements of biogenic amines and metabolites in the CSF of suicide victims and nonsuicides, in: H.-J. Möller (Ed.), Current Issues of Suicidology, Springer, Berlin, Heidelberg, New York, Tokyo, 1988.
27. T. Abletshauser, Die 5-Hydroxytryptamin-Konzentration in der cerebrospinalen Flüssigkeit bei suizidaler und nichtsuizidaler Todesursache unter besonderer Berücksichtigung der Opiatabhängigkeit, Thesis, Ludwig-Maximilians-Universität München, 1995.
28. Gjerris A., Sorensen A.S., Rafaelsen O.J., Werdelin L., Alling C., Linnoila M. 5-HT and 5-HIAA in cerebrospinal fluid in depression. J. Affect. Disord. 12:1987;13-22
29. Ahtee L., Attila L.M.J. Cerebral monoamine neurotransmitters in opioid withdrawal and dependence. Med. Biol. 65:1987;113-119
30. Kiyatkin E.A. Neurophysiology and neurochemistry of drug dependence: a review. Int. J. Neurosci. 44:1989;283-316
31. Ahtee L., Attila P., Lauhakangas V., Solkinen A., Sipilä J. The fall of homovanillic acid and 5-hydroxyindoleacetic acid concentrations in brain of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration. J. Neural Transm. 68:1987;63-78
32. Munn E.M., Borszcz G.S. Increases in the release and metabolism of serotonin in nucleus parafascicularis thalami following systemically administered morphine in the rat. Neurosci. Lett. 332:2002;151-154
33. Tao R., Auerbach S.B. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux the central nervous system. J. Pharmacol. Exp. Ther. 303:2002;704-710
34. Taylor B.K., Basbaum A.I. Systemic morphine-induced release of serotonin. J. Neurochem. 86:2003;1129-1141
35. Algeri A., Consolazione A., Calderini G., Achilli G., Puche Canas E., Garattini S. Effect of the administration of (d-Ala)2 methionine-enkephalin on the serotonin metabolism in rat brain. Experientia. 34:1978;1488-1489
36. Garcia-Sevilla J.A., Ahtee L., Magnusson T., Carlsson A. Opiate-receptor mediated changes in monoamine synthesis in rat brain. J. Pharm. Pharmacol. 30:1978;613-621
37. Loh H.H., Shen F.-H., Way E.L. Inhibition of morphine tolerance and physical dependence development and brain serotonin synthesis by cycloheximide. Biochem. Pharmacol. 18:1969;2711-2721
38. Shen F.H., Loh H.H., Way E.L. Brain serotonin turnover in morphine tolerant and dependent mice. J. Pharmacol. Exp. Ther. 175:1970;427-434
39. Matos F.F., Rollema H., Basbaum A.I. Simultaneous measurement of extracellular morphine and serotonin in brain tissue and CSF by microdialysis in awake rats. J. Neurochem. 58:1992;1773-1781
40. Ahtee L. Chronic morphine administration decreased 5-hydroxytryptamine and 5-hydroxyindolacetic acid content in the brain of rats. Med. Biol. 58:1980;38-44
41. Bowers M.B. Jr., Kleber H.D., Davis L. Acid monoamine metabolites in cerebrospinal fluid during methadone maintenance. Nature. 232:1971;581-582
42. Caille S., Espejo E.F., Koob G.F. Dorsal and median raphe serotonergic system lesion does not explain opiate withdrawal syndrome. Pharmacol. Biochem. Behav. 72:2002;979-986
43. Haubrich D.R., Blake D.E. Modification of serotonin metabolism in rat brain after acute and chronic administration of morphine. Biochem. Pharmacol. 22:1973;2753-2759
44. Theiss P., Papeschi R., Herz A. Effects of morphine on the turnover of brain catecholamines and serotonin in rats - chronic morphine administration. Eur. J. Pharmacol. 34:1975;263-271
45. Yarbrough G.G., Buxbaum D.M., Sanders-Bush E. Biogenic amines and narcotic effects II. Serotonin turnover in the rat after acute and chronic morphine administration. J. Pharmacol. Exp. Ther. 185:1973;328-335
46. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry. 28:1995;45-50
47. Palaniappan V., Ramachandran V., Somasundaram O. Suicidal ideation and biogenic amines in depression. Indian J. Psychiatry. 25:1983;286-292
48. Banki C.B., Arato M., Papp Z., Kurcz M. Biochemical markers in suicidal patients. J. Affect. Disord. 6:1984;341-350
49. Walendzik H., Zimmer G., Skopp G. Serotonin-, 5- Hydroxyindolessigsäure- und Cholesteringehalt in Blut, Liquor und Hirnarealen zur Abgrenzung suizidaler von nicht suizidalen Todesfällen. Arch. Krim. 205:2000;131-144
50. Asberg M., Thoren P., Träskman L., Bertilsson L., Ringberger V.-A. "Serotonin depression" - a biochemical subgroup within the affective disorders? Science. 191:1976;478-480
51. Träskman L., Asberg M., Bertilsson L., Sjöstrand L. Monoamine metabolites in CSF and suicidal behaviour. Arch. Gen. Psychiatry. 38:1981;631-636
52. Berrettini W.H., Nurnberger J.I. Jr., Narrow W., Simmons-Alling S., Gershon E.S. Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann. N. Y. Acad. Sci. 487:1986;197-201
53. Agren H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide Psychiatry Res. 3:1980;225-236
54. Roy-Byrne P., Post R.M., Rubinow D.R., Linnoila M., Savard R., Davis D. CSF 5-HIAA and personal and family history of suicide in affectively ill patients. Psychiatry Res. 10:1983;263-274
55. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., Goodwin F.K. Low cerebrospinal fluid 5-hydroxyindolacetic acid concentration differentiates impulsive from nonimpulsive violent behaviour. Life Sci. 33:1983;2609-2614
56. van Praag H.M., Plutchik R., Conte H. The serotonin hypothesis of (auto)aggression. Critical appraisal of the evidence. Ann. N. Y. Acad. Sci. 487:1986;150-167
57. H.R. Bourne, W.E. Bunney, R.W. Colburn, J.M. Davis, Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients, Lancet 2 (7572) (1968) 805-808.
58. Brunner J., Stalla G., Stalla J. Parameter des Hypothalamus-Hypophysen- Nebennierenrinden-Systems im Liquor und im Plasma bei Patienten nach Suizidversuch und mit Suizidideen. Neurobiologie suizidalen Verhaltens, S. Roderer Verlag, Regensburg. 11:2001;161-181
59. M. Asberg, P. Nordström, L. Träskman-Bendz, Biological factors in suicide, in: A. Roy (Ed.), Suicide, Williams and Wilkins, Baltimore, MD, 1986, pp. 47-70.
60. Tao R., Auerbach S.B. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux the central nervous system. J. Pharmacol. Exp. Ther. 303:2002;704-710
61. Montgomery S.A., Montgomery D.B. Pharmacological prevention of suicidal behaviour. J. Affect. Disord. 4:1982;291-298
62. Agren H. Life at risk: markers of suicidality in depression. Psychiatr. Dev. 1:1983;87-104
63. Roy A., Agren H., Pickar D. Reduced CSF concentrations of homovanillic acid and homovallinic acid to 5-hydroxyindolacetic acid ratios in depressed patients: relationship to suicidal behaviour and dexamethasone nonsuppression. Am. J. Psychiatry. 143:1986;1539-1545
64. Roy A., Pickar D., DeJong J., Karoum F., Linnoila M. Suicidal behaviour in depression: relationship to noradrenergic function. Biol. Psychiatry. 25:1989;341-350
65. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry. 45:1988;577-579
66. Hucks D., Lowther S., Crompton M.R., Katona C.L.E., Horton R.W. Corticotropin-releasing factor binding sites in cortex depressed suicides. Psychopharmacology. 134:1997;174-178
67. Lopez J.F., Palkovits M., Arato M., Mansour A., Akil H., Watson S.J. Localization and quantification of pro-opiomelanocortin mRNA and glucocorticoid receptor mRNA in pituitaries of suicide victims. Neuroendocrinology. 56:1992;491-501
68. F. Holsboer, Neuroendocrinology of affective disorder, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: the Fourth Generation of Progress, Raven Press, New York, 1995, pp. 957-969.
69. Norman W.H., Brown W.A., Miller I.W., Keitner G.I., Overholser J.C. The dexamethasone suppression test and completed suicide. Acta Psychiatr. Scand. 81:1990;120-125
70. Lester D. The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry. 25:1992;265-270
71. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality. A quantitative review of primary prevention trials. Br. Med. J. 301:1990;309-314
72. Muldoon M.F., Rossouw J.E., Manuck S.B., Glueck C.J., Kaplan J.R., Kaufman P.G. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism. 42:1993;45-56
73. Zureik M., Courbon D., Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study. Br. Med. J. 313:1996;649-651
74. Boston P.F., Dursun S.M., Reveley M.A. Cholesterol and mental disorder. Br. J. Psychiatr. 169:1996;682-689
75. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry. 28:1995;45-50
76. Brown R.P., Stoll P.M., Stokes P.E., Frances A., Sweeney J., Kocsis J.H., Mann J.J. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res. 23:1988;167-178
77. Coryell W., Schlesser M. The dexamethasone suppression test and suicide prediction. Am. J. Psychiatry. 158:2001;748-753
78. Price M.L., Curtis A.L., Kirby L.G., Valentino R.J., Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology. 18:1998;492-502
79. Golomb B.A. Cholesterol and violence: is there a connection? Ann. Intern. Med. 128:1998;478-487
80. Golomb B.A., Stattin H., Mednick S. Low cholesterol and violent crime. J. Psychiatr. Res. 34:2000;301-309
81. Kim Y., Lee H., Kim J. Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatr. Scand. 105:2002;141-148
82. Kaplan J.R., Shively C.A., Fontenot M.B., Morgan T.M., Howell S.M., Manuck S.B., Muldoon M.F., Mann J.J. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behaviour in monkeys. Psychosom. Med. 56:1994;479-484
83. Kaplan J.R., Muldoon M.F., Manuck S.B., Mann J.J. Assessing the observed relationship between low cholesterol and violence-related mortality. Implications for suicide risk. Ann. N. Y. Acad. Sci. 836:1997;57-80
84. Brunner J., Parhofer K., Schwandt P., Bronisch T. Cholesterol, omega-3-fatty acids, and suicide risk: empirical evidence and pathophysiological hypothese. Fortschr. Neurol. Psychiatr. 69:2001;460-467
85. E.F. Coccaro, Central serotonin and impulsive aggression. Br. J. Psychiatry (Suppl 8) (1989) 52-62.
86. Coccaro E.F., Siever L.J., Klar H.M., Maurer G., Cochrane K., Cooper T.B., Mohs R.C., Davis K.L. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behaviour. Arch. Gen. Psychiatry. 46:1989;587-599
87. Mann J.J., McBride P.A., Malone K.M., DeMeo M., Keilp J. Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology. 13:1995;53-64
88. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 17:1997;8451-8458
89. Arango V., Underwood M.D., Mann J.J. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol. Psychiatry. 39:1996;112-120
90. Ordway G.A., Smith K.S., Haycock J.W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62:1994;680-685
91. Weiss J.M., Stout J.C., Aaron M.F., Quan N., Owens M.J., Butler P.D., Nemeroff C.B. Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res. Bull. 35:1994;561-572
92. Roy A., Nielsen D., Rylander G. Genetics of suicide in depression. J. Clin. Psychiatry. 60:1999;12-17
93. Roy A., Rylander G., Sarchiapone M. Genetics of suicide: family studies and molecular genetics. Ann. N. Y. Acad. Sci. 836:1997;135-157